Unknown NA INTERVENTIONAL 2-arm NCT04431375

Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV

Sponsor: Institute of Liver and Biliary Sciences, India

Conditions Acute-On-Chronic Liver Failure Hepatitis B

Interventions Fecal Mircobiota Transplantation Plasma Exchange Tenofovir

Updated 7 times since 2020 Last updated: Jan 27, 2022 Started: Jun 22, 2020 Primary completion: Jun 10, 2022 Completion: Jun 10, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Acute-On-Chronic Liver Failure and Hepatitis B and is currently ongoing. Institute of Liver and Biliary Sciences, India leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Feb 2024 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Feb 2022 — Feb 2024 [monthly]

Recruiting NA
Jan 2021 — Feb 2022 [monthly]

Recruiting NA

▶ Show 2 earlier versions

Sep 2020 — Jan 2021 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Jul 2020 — Sep 2020 [monthly]

Not Yet Recruiting NA

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Liver and Biliary Sciences, India

Data source: Institute of Liver and Biliary Sciences, India

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Delhi, India